Coegin Pharma AB (7Z6)
Market Closed
10 Aug, 06:09
XFRA XFRA Primary XSTU €
0. 26
+0.11
+73.3333%
€
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
- Eps
€ 0.15
Previous Close Want to track 7Z6 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
7Z6 closed Monday higher at €0.26, an increase of 73.3333% from Friday's close, completing a monthly decrease of -16.9329% or -€0.05. Over the past 12 months, 7Z6 stock lost -33.5038%.
7Z6 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).
7Z6 Chart
Coegin Pharma AB (7Z6) FAQ
What is the stock price today?
The current price is €0.26.
On which exchange is it traded?
Coegin Pharma AB is listed on XFRA.
What is its stock symbol?
The ticker symbol is 7Z6.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Coegin Pharma AB ever had a stock split?
No, there has never been a stock split.
Coegin Pharma AB Profile
| Biotechnology Industry | Healthcare Sector | Mr. Jens Eriksson CEO | XFRA Exchange | SE0020357754 ISIN |
| Sweden Country | 1 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Coegin Pharma AB is a pioneering biotechnology firm that specializes in the inception and advancement of dermacosmetic products alongside pharmaceuticals aimed at tackling severe health conditions such as diabetes and cancer. With its foundational roots laid down in 2005, Coegin Pharma AB is strategically positioned in Lund, Sweden, making significant strides in the biotechnology industry through innovative research and development efforts.
Products and Services
- AVX001 GEL: This drug candidate has progressed to phase 2 clinical studies for the management of actinic keratosis and is in the phase 1 clinical evaluation stage for the treatment of basal cell carcinoma. Actinic keratosis, a precursor to skin cancer, and basal cell carcinoma, a form of skin cancer, represent significant challenges in dermatological oncology. AVX001 GEL's development is aimed at providing effective treatments for these conditions.
- AVX420: Currently in the preclinical study phase, AVX420 is being explored as a potential therapeutic intervention for leukemia. Leukemia, a cancer of the body's blood-forming tissues, presents a critical need for new and innovative treatments. The development of AVX420 encapsulates Coegin Pharma’s commitment to contributing to leukemia care.
- FOL026: This peptide-based drug is under preclinical study for its potential to prevent cardiovascular complications in patients with diabetes. Given the high prevalence of diabetes globally and the associated risk of cardiovascular diseases, FOL026 could represent a significant advancement in preventing such life-threatening complications.
- AVX420/FOL026 therapy: In the preclinical study phase, this dual therapy is being researched for its efficacy in treating kidney and liver fibrosis. Fibrosis of these organs is a critical concern in various systemic diseases, and effective treatment options are highly sought-after. The dual therapeutic approach signifies Coegin Pharma's innovative strategy in addressing complex health challenges.
- FOL005: Aimed at stimulating hair growth, FOL005 is being developed as a solution for hair loss issues. Hair loss can significantly affect individuals' quality of life, and Coegin Pharma is working on providing a new hope for those suffering through the development of FOL005.
Contact Information
Address: Medicon Village
Phone: 45 61 90 50 66
Website: https://coeginpharma.com
